Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Cooke P et al. | 1981 | intact cell/cell culture, human blood cells | static magnetic field, DC, MRI | 0.5–1 T |
Kubinyi G et al. | 2010 | intact cell/cell culture, human blood samples | static magnetic field, co-exposure | 2.8–476.7 mT |
Belyaev IYa et al. | 1997 | intact cell/cell culture, human diploid fibroblast cells | static magnetic field, shielding/field deprivation | 0.15 µT |
Yagci F et al. | 2016 | intact cell/cell culture, human gingival fibroblasts | static magnetic field | 95.6–148.1 mT |
Szerencsi A et al. | 2013 | intact cell/cell culture, human leukocytes | RF field, static magnetic field, MRI, therapeutic/medical device | 3 T |
Tofani S et al. | 1995 | intact cell/cell culture, human lymphocytes | magnetic field, static magnetic field, 50/60 Hz, DC, co-exposure, shielding/field deprivation | 42–150 µT |
Ardito G et al. | 1984 | intact cell/cell culture, human lymphocytes | static magnetic field | 74 mT |
Sarimov R et al. | 2011 | intact cell/cell culture, human lymphocytes | magnetic field, static magnetic field, 50/60 Hz, DC | 20–43 µT |
Reddig A et al. | 2015 | intact cell/cell culture, human lymphocytes | static magnetic field, MRI, co-exposure | - |
Yuan LQ et al. | 2020 | intact cell/cell culture, human nephroblastoma cell line G401, human embryonic renal epithelial cell line HEK293, human lung cancer cell line A549, human bronchial epithelial cell line BEAS-2B, human gastric cancer cell line SGC-7901, human gastric epithelial cell line GES-1, human pancreatic cancer cell line PANC-1, human pancreatic ductal epithelial cell line HPDE6-C7, wild-type (WT) mouse embryonic fibroblast (MEF) cells, NBS1-/-MEF and MDC1-/-MEF cells | static magnetic field, magnetic field, 50/60 Hz, co-exposure | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.